Long-term effects of empagliflozin in patients with chronic kidney disease
<p><strong>Background:</strong> In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to asses...
Príomhchruthaitheoirí: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Rannpháirtithe: | |
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
Massachusetts Medical Society
2024
|